Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nationwide Children's Hospital
With
AskBio Inc
This phase I randomized double blind dose escalation study investigates the safety and efficacy of the mini-dystrophin gene transferred to the biceps muscle for Duchenne muscular dystrophy patients, ages 5 to 12 years of age, using a recombinant adeno-associated virus. Eligible participants must have a known dystrophin gene mutation and may be concurrently treated with corticoid steroids. The mini-dystrophin gene or a placebo agent (normal saline or empty viral capsids) are injected directly into both biceps muscles while under conscious sedation. Following the gene transfer, patients are admitted to the hospital for 48 hours of observation followed by weekly outpatient visits at the Columbus Children's Hospital Neuromuscular Clinic. A bilateral muscle biopsy is preformed following 6 weeks with long term follow up will consisting of bi-annual visits for the next 2 years.
Age
5–15
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Known null mutation of the Dystrophin gene
Male age of 5 years or older
If taking corticosteroids, must have dose unchanged for the past 3 months
Serum creatine kinase elevation greater than 10x normal value (established by Children's Hospital)
Progressive, symmetrical proximal muscle weakness of arms and legs
You may not be if
Unable to cooperate for muscle strength testing
Joint contractures that prohibit muscle strength testing
Concomitant illness
Individuals predisposed to excessive vagal responses (bradyarrhythmia or hypotension)